UNION therapeutics, a clinical-stage diversified pharmaceutical company focusing on immunology and infectious diseases, said that it has enrolled the first patient in the IASOS phase 2b study of oral orismilast in psoriasis patients. The US Food and Drug Administration had recently approved UNION’s investigational new drug program for advancing oral orismilast into a Phase 2b trial in patients with moderate to severe psoriasis. The company said that the primary aim of the phase 2b trial is to study the safety and efficacy of the drug while also looking into identifying the appropriate dose regimen for phase 3 studies. According to Union Therapeutics, the drug holds potential to be a game-changer for psoriasis treatments, which is an autoimmune disease.